Brentuximab vedotin

Drug Profile

Brentuximab vedotin

Alternative Names: Adcetris; cAC10-vcMMAE; SGN-35

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Seattle Genetics
  • Developer Bristol-Myers Squibb; Fondazione Italiana Linfomi; Lymphoma Academic Research Organisation; Seattle Genetics; Takeda; Takeda Oncology; Virginia Commonwealth University
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Hodgkin's disease; Anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Hodgkin's disease
  • Phase III Cutaneous T cell lymphoma; T cell lymphoma
  • Phase II Diffuse large B cell lymphoma; Germ cell and embryonal neoplasms; Peripheral T-cell lymphoma; Systemic lupus erythematosus
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Graft-versus-host disease; Mycosis fungoides; Sezary syndrome
  • Discontinued Leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Dec 2016 Seattle Genetics plans a sBLA for Cutaneous T-cell lymphoma in USA
  • 05 Dec 2016 Efficacy and adverse events data from a phase II trial in Anaplastic large cell lymphoma presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH-2016)
  • 05 Dec 2016 Updated efficacy and adverse events data from a phase I trial in Non-Hodgkin's lymphoma presented at the 58th American Society of Hematology Annual Meeting and Exposition (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top